Renaissance Capital logo

Aziyo Biologics Priced, Nasdaq: AZYO

Makes regenerative medical products for various tissue types.

Industry: Health Care

Latest Trade: $6.77 -0.30 (-4.2%)

First Day Return: -14.7%

Return from IPO: -58.4%

Industry: Health Care

We are a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material. Our proprietary products, which we refer to as our Core Products, are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction markets, which represented a combined $3 billion market opportunity in the United States in 2019. To expand our commercial reach, we have commercial relationships with major medical device companies, such as Boston Scientific and Medtronic, to promote and sell some of our Core Products. We believe our focus on our unique regenerative medicine platforms and our Core Products will ultimately maximize our probability of continued clinical and commercial success and will create a long-term competitive advantage for us.
more less
IPO News for Aziyo Biologics
more
IPO Data
IPO File Date 09/14/2020
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 2.9
Deal Size ($mm) $50
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/07/2020
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 2.9
Deal Size ($mm) $50
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Silver Spring, MD
Founded 2015
Employees 151
Website www.aziyo.com